Shivani Chandra

Shivani Chandra

Auto-generated profile, based on publicly available information

Shivani Chandra

Government of India – WHO TB Technical Support Network, Office of the World Health Organization (WHO) Representative to India

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Indian Journal of Medical Research
Verified
Journal Article
Open access
PDF file
NSNandini Sharma
Nandini Sharma
AKAshwani Khanna
Ashwani Khanna
SCShivani Chandra
Shivani Chandra
SBSaurav Basu
Saurav Basu
KCKamal K. Chopra
Kamal K. Chopra
CKCharu Kohli
Charu Kohli
Background & objectives: The increase in the burden of multidrug-resistant tuberculosis (MDR-TB) is a matter of grave concern. The present study was undertaken to describe MDR-TB treatment outcome trends in Delhi and their epidemiological correlates, to assess the adequacy of treatment records and to also generate evidence towards influencing and improving practices related to the MDR-TB control programme. Methods: A retrospective record-based study (2009-2014) was conducted in three major drug resistance TB treatment centres of Delhi. Treatment outcomes and adverse effects were extracted from the existing programme records including patients’ treatment cards and laboratory registers. Results: A total of 2958 MDR-TB patients were identified from the treatment cards, of whom 1749 (59.12%) were males. The mean (±standard deviation) age was 30.56±13.5 years. Favourable treatment outcomes were reported in 1371 (53.28%) patients, but they showed a declining trend during the period of observation. On binomial logistic regression analysis, patients with age ≥35 yr, male sex and undernourishment (body mass index <18.5) at the time of treatment initiation had a significantly increased likelihood of unfavourable MDR-TB treatment outcome (P<0.001). Interpretation & conclusions: The study showed an increasing burden of MDR-TB patients, especially in the young population with increased risk of transmission posing a major challenge in achieving TB elimination targets.

28 July 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
KJKathiresan Jeyashree
Kathiresan Jeyashree
JTJeromie Thangaraj
Jeromie Thangaraj
KRKiran Rade
Kiran Rade
BMBhavesh Modi
Bhavesh Modi
SSSriram Selvaraju
Sriram Selvaraju
MMManoj Vasant Murhekar
Manoj Vasant Murhekar
Objectives: We verified subnational (state/union territory (UT)/district) claims of achievements in reducing tuberculosis (TB) incidence in 2020 compared with 2015, in India.Design: A community-based survey, analysis of programme data and anti-TB drug sales and utilisation data.Setting: National TB Elimination Program and private TB treatment settings in 73 districts that had filed a claim to the Central TB Division of India for progress towards TB-free status.Participants: Each district was divided into survey units (SU) and one village/ward was randomly selected from each SU. All household members in the selected village were interviewed. Sputum from participants with a history of anti-TB therapy (ATT), those currently experiencing chest symptoms or on ATT were tested using Xpert/Rif/TrueNat. The survey continued until 30 Mycobacterium tuberculosis cases were identified in a district.Outcome measures: We calculated a direct estimate of TB incidence based on incident cases identified in the survey. We calculated an under-reporting factor by matching these cases within the TB notification system. The TB notification adjusted for this factor was the estimate by the indirect method. We also calculated TB incidence from drug sale data in the private sector and drug utilisation data in the public sector. We compared the three estimates of TB incidence in 2020 with TB incidence in 2015.Results: The estimated direct incidence ranged from 19 (Purba Medinipur, West Bengal) to 1457 (Jaintia Hills, Meghalaya) per 100 000 population. Indirect estimates of incidence ranged between 19 (Diu, Dadra and Nagar Haveli) and 788 (Dumka, Jharkhand) per 100 000 population. The incidence using drug sale data ranged from 19 per 100 000 population in Diu, Dadra and Nagar Haveli to 651 per 100 000 population in Centenary, Maharashtra.Conclusion: TB incidence in 1 state, 2 UTs and 35 districts had declined by at least 20% since 2015. Two districts in India were declared TB free in 2020.

1 October 2015 in Indian Journal of Tuberculosis
Verified
Journal Article
Closed access
SNSreenivas Achuthan Nair
Sreenivas Achuthan Nair
KSK.S. Sachdeva
K.S. Sachdeva
PMParmar Malik
Parmar Malik
SCS. Chandra
S. Chandra
RRR. Ramachandran
R. Ramachandran
SKS.D. Khaparde
S.D. Khaparde

29 September 2026 in The BRICS Health Journal
Verified
Journal Article
Open access
PDF file
AFAsha Frederick
Asha Frederick
MRMinitta Maria Regy
Minitta Maria Regy
NTNikkin Thiliban
Nikkin Thiliban
SAShanta Achanta
Shanta Achanta
DDDhrubajyoti Deka
Dhrubajyoti Deka
SRShobini Rajan
Shobini Rajan
Tuberculosis (TB) programmatic outcomes are heavily influenced by heterogeneous disease distribution and localized variations in loss to follow-up (LFU). While routine electronic surveillance provides robust epidemiological totals, it may mask localized patterns of treatment attrition. Aim. To develop an operational geospatial intelligence framework using secondary surveillance data to identify and map LFU hotspots and establish a risk-stratified model for targeted programmatic prioritization. Materials and Methods. This retrospective operational research study analyzed anonymized treatment outcome records from TB patients ( n = 92,824) in Tamil Nadu, 2022. Treatment outcomes were aggregated across 234 tuberculosis units (TU) in 35 districts and integrated into a Geographic Information System framework. Spatial autocorrelation (Global Moran’s I), Getis-Ord Gi* hotspot analysis, and Kernel Density Estimation were applied to identify LFU clusters. Spatial outputs were integrated with core epidemiological indicators within a risk-stratification framework. Results. Spatial analysis demonstrated significant positive spatial autocorrelation (Global Moran’s I, p < 0.001) and marked heterogeneity in LFU across Tamil Nadu. Getis-Ord Gi* analysis identified statistically significant hotspots (95–99% confidence). District Tuberculosis Centre Vellore showed the highest LFU proportion (12.0%), with additional priority TU identified across Villupuram, Krishnagiri, Coimbatore, Perambalur, and Trichy. Villupuram contributed three hotspot TU. Overall, 8 TU (3.4%) as high-risk programme areas, providing a basis for more focused programme review and prioritisation. Conclusion. Geospatial analytics directly compliments routine TB surveillance by replacing uniform programmatic strategies with data-driven, geographically targeted actions. This framework offers a scalable, replicable model to improve treatment retention and accelerate TB elimination targets across high-burden settings.